Table 2 Compliance with chemotherapy
Total | C1750 mg/m2 | C1500 mg/m2 | |
|---|---|---|---|
n = 49 | n = 19 | n = 30 | |
Reason for discontinuation of chemotherapy, n (%) | |||
Progression | 12 (24.5) | 4 (21.1) | 8 (26.7) |
Need for surgery | 6 (12.2) | 2 (10.5) | 4 (13.3) |
Death (treatment-related cause) | 3 (6.1) | 1 (5.3) | 2 (6.7) |
Other toxicity | 16 (32.7) | 5 (26.3) | 11(36.7) |
Patient or investigator decision not otherwise specified | 11 (22.4) | 7 (36.8) | 4 (13.3) |
Still on treatment | 1 (2.0) | 0 (0.0) | 1 (3.3) |
Receipt ofat least 75% of planned dose in first two cycles, n (%) | |||
Each drug separately | |||
Capecitabine | 42 (85.7) | 18 (94.7) | 24 (80.0) |
Oxaliplatin | 46 (93.9) | 19 (100.0) | 27 (90.0) |
Bevacizumab | 44 (89.8) | 17 (89.5) | 27 (90.0) |
All three drugs | 40 (82.6) | 16 (84.0) | 24 (80.0) |
Dose intensity while on chemotherapy, median (IQ range) | |||
Capecitabine | 0.95 (0.66, 1) | 0.8(0.57,1) | 0.96 (0.67,1) |
Oxaliplatin | 1 (0.8, 1) | 0.8 (0.67,1) | 1 (1,1) |
Bevacizumab | 1 (0.8, 1) | 0.8 (0.67,1) | 1 (1,1) |